Loading
A phase 3 trial of carboplatin, paclitaxel / nab-paclitaxel and nivolumab in lung cancer, run by Fundación GECP, active but no longer recruiting.
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy is a phase 3, randomised interventional study registered as NCT04564157 by Fundación GECP, with a registry enrolment figure of 210 participants, started 2021-01-13 and due to reach its primary completion in 2030-04-01. Interventions recorded: Carboplatin; Paclitaxel; Nivolumab. Conditions listed: Non-Small Cell Lung Cancer; Adjuvant Chemotherapy. Primary outcome: The disease-free survival. Lung eligibility wording from the registry: "Patients diagnosed of primary non-small cell lung cancer, histologically confirmed". Sites: Spain. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Paclitaxel / nab-paclitaxel, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Paclitaxel / nab-paclitaxel, Platinum agents and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Paclitaxel / nab-paclitaxel, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Paclitaxel / nab-paclitaxel, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Paclitaxel / nab-paclitaxel, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.